In parallel with advances in cancer biology, anti-cancer drug discovery has focused recently on targets related to cell cycle progression and signal transduction. In particular, targeting signalling pathways (e.g. Hedgehog, Wnt, Notch) or cancer cells represents a promising strategy to develop effective and innovative drug candidates. However, the major types of solid human tumour are multi-causal in nature and so their treatment with “mechanism-based” agents alone is unlikely to be fully effective. Instead, improved treatment strategies involving combination therapies, such as signal transduction inhibitors with new generation antimitotic compounds, are anticipated in the clinic. Antitumor agents targeting tubulin cause aberrant mitotic spindle formation, cell cycle arrest in mitosis and induction of apoptosis. Besides taxol, other NP such as epothilones, vincristine, vinblastine and the marine macrolide zampanolide have provided new perspectives for the development of a new generation of clinical anticancer agents.  



To access your WG3 please log in


Milica Pešić     (Group leader)
Ali Osmay Gure
José Fernando Díaz Pereira
Engin Ulukaya
Magdalena Król
Jana Lomenova-Viskupicova
Lubica Horakova
 Milica Pešić,  Anna Podolski-Renić,  Jelena Dinić
Istvan Zupkó
Shani Doron
Michel, Steinmetz
Yusuf Tutar
Walter Kolch
Wojciech Rode
Wolfgang Link
Mely Yves
Stephen J. Fey
Daumantas Matulis
 Marian Hajduch
Maria Jesus Perez
Christoph Wiesner
Al-Jamal Khuloud
John Stephens
Christian Spieri